• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by AlloVir Inc.

    2/24/25 11:51:57 AM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001681782
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Allovir, Inc.
    SEC File Number
    001-39409
    Address of Issuer
    1100 Winter Street
    Waltham
    MASSACHUSETTS
    02451
    Phone
    617-433-2605
    Name of Person for Whose Account the Securities are To Be Sold
    Hagen Brett R
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Morgan Stanley Smith Barney LLC
    1 New York Plaza, 38th Floor
    New York � NY � 10004
    96967504085102/21/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common02/21/2025Restricted StockAllovir, Inc.Checkbox not checked9602/21/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Brett Hagen
    c/o 1100 Winter Street
    Waltham � MA � 02451
    Restricted Stock01/23/202536341
    Brett Hagen
    c/o 1100 Winter Street
    Waltham � MA � 02451
    Restricted Stock01/10/202514146
    Brett Hagen
    c/o 1100 Winter Street
    Waltham � MA � 02451
    Restricted Stock11/19/202413554

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/24/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Brett Hagen

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ALVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVR

    DatePrice TargetRatingAnalyst
    12/26/2023$17.00 → $1.00Buy → Underperform
    BofA Securities
    12/22/2023Outperform → Market Perform
    Leerink Partners
    12/22/2023Overweight → Underweight
    JP Morgan
    12/22/2023Overweight → Neutral
    Piper Sandler
    8/18/2023$17.00Buy
    BofA Securities
    2/10/2022$32.00 → $30.00Outperform
    SVB Leerink
    1/18/2022$48.00 → $45.00Overweight
    Morgan Stanley
    12/17/2021$37.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $ALVR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AlloVir Inc.

      SC 13G - Allovir, Inc. (0001754068) (Subject)

      10/11/24 4:02:13 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AlloVir Inc.

      SC 13G/A - Allovir, Inc. (0001754068) (Subject)

      8/2/24 6:25:25 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by AlloVir Inc. (Amendment)

      SC 13G/A - Allovir, Inc. (0001754068) (Subject)

      2/13/24 4:54:00 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      3/4/24 5:37:52 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      2/28/24 1:06:25 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

      Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s

      12/22/23 7:00:00 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AlloVir downgraded by BofA Securities with a new price target

      BofA Securities downgraded AlloVir from Buy to Underperform and set a new price target of $1.00 from $17.00 previously

      12/26/23 7:17:53 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir downgraded by Leerink Partners

      Leerink Partners downgraded AlloVir from Outperform to Market Perform

      12/22/23 10:47:30 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir downgraded by JP Morgan

      JP Morgan downgraded AlloVir from Overweight to Underweight

      12/22/23 9:11:15 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by AlloVir Inc.

      SCHEDULE 13D - Kalaris Therapeutics, Inc. (0001754068) (Subject)

      3/25/25 7:40:09 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.

      SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)

      3/20/25 4:32:25 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Leadership Update, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Regulation FD Disclosure

      8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)

      3/18/25 5:04:06 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Hagen Brett R sold $8,135 worth of shares (907 units at $8.97), decreasing direct ownership by 32% to 1,925 units (SEC Form 4)

      4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/27/25 7:19:58 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Akkaraju Srinivas claimed ownership of 3,578 shares (SEC Form 3)

      3/A - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/26/25 5:06:57 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Samsara Biocapital Gp, Llc claimed ownership of 11,448,081 shares (SEC Form 3)

      3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)

      3/25/25 7:38:53 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVR
    Leadership Updates

    Live Leadership Updates

    See more
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      3/4/24 5:37:52 PM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      2/28/24 1:06:25 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

      - Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology

      5/16/23 7:00:00 AM ET
      $ALVR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care